Cowen Reiterates Outperform Rating and $48 PT on Abbott Labs (ABT) Following Q1 Report; 'Expect Sequentially Improving Sales Growth'
Tweet Send to a Friend
Cowen reiterates Outperform rating and $48 price target on Abbott Labs (NYSE: ABT) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
